Prime editing in the human body reaches its first clinical trial

Editing a faulty gene without removing a single cell from the patient's body is one of the most ambitious goals of genetic medicine. Now, prime editing in the human body has reached an important milestone: its first clinical use.

On October 5, 2026, US biotechnology company Prime Medicine announced that the first patient with Wilson disease had received PM577a, an experimental therapy designed to correct a specific mutation in liver cells. Nature reported on the development on October 22.

This is the first known clinical administration of a prime-editing treatment intended to modify DNA directly inside the body. Prime editing had previously been used to modify patients' cells outside the body, but this approach aims to deliver the molecular machinery to the relevant cells without removing them.

The announcement confirms that a patient has received the treatment. It does not yet establish whether the intended DNA change occurred, whether it was sufficiently efficient, or whether the patient benefited clinically.

That distinction is essential to understanding both the achievement and the questions the trial must answer.

A single DNA letter can disrupt copper metabolism

Wilson disease is a rare inherited disorder in which the body loses its ability to eliminate excess copper efficiently.

Copper is an essential micronutrient. Many enzymes depend on it, but too much copper is toxic.

Normally, a protein called ATP7B helps liver cells move excess copper into bile, allowing it to leave the body. In people with Wilson disease, disease-causing variants affecting both copies of the ATP7B gene disrupt this process.

Copper gradually accumulates in the liver and can eventually damage the brain and other tissues. Untreated disease may lead to severe liver injury, cirrhosis, and neurological complications.

Existing treatments can control copper levels. Some medicines bind copper and promote its removal, while others reduce its absorption. These treatments have substantially improved the outlook for patients, but they generally require lifelong use.

PM577a takes a different approach. Instead of repeatedly managing copper accumulation, it is intended to repair a genetic defect responsible for the underlying problem.

The treatment targets a mutation known as H1069Q, one of the most common Wilson disease variants in Europe and North America.

The mutation involves a single nucleotide substitution in ATP7B, causing an amino acid change that impairs the resulting protein's function.

The goal is to restore the correct DNA sequence in liver cells so that they can once again produce functional ATP7B and transport copper normally.

Rewriting DNA without breaking both strands

Conventional CRISPR-Cas9 editing often uses a protein that cuts both strands of DNA at a targeted location.

This is useful for disabling genes, but precisely replacing an incorrect DNA letter with the correct one is more demanding.

In 2019, researchers led by Andrew Anzalone and David Liu described prime editing in Nature. The method introduced a more versatile way to write specific changes into the genome.

The system combines a modified Cas9 protein, which makes a cut in only one DNA strand, with an enzyme called reverse transcriptase.

A specially engineered guide RNA identifies the target and carries the instructions for the desired genetic change.

Together, these components allow the editor to locate a particular DNA sequence and write a specified correction.

Unlike conventional CRISPR cutting, prime editing does not require creating a double-strand DNA break. It can perform several kinds of small genomic changes, including substitutions, insertions, and deletions.

This flexibility makes it attractive for correcting mutations that are difficult to address using other editing platforms.

But a molecular system that works in cultured cells is only part of the challenge.

To treat an inherited liver disease, the machinery must reach enough of the right cells, operate efficiently, and avoid clinically significant unintended effects.

PM577a is designed to address that delivery problem through a single intravenous infusion.

Its editing components are packaged in lipid nanoparticles, microscopic carriers engineered to deliver molecular cargo to liver cells.

Once inside the cell, the editor is intended to recognize the H1069Q mutation and restore the required nucleotide sequence.

No cells need to be removed from the patient, modified in a laboratory, and infused back into the body. The genome editing is intended to happen entirely in vivo.

Promising animal data, unanswered human questions

Before starting clinical testing, Prime Medicine evaluated its approach in laboratory and animal models.

According to preclinical results reported by the company, studies using mice carrying a humanized version of the mutant ATP7B gene achieved precise correction in more than 80% of hepatocytes under the reported experimental conditions.

The company also reported restoration of copper metabolism toward levels seen in healthy animals.

These findings provide a rationale for clinical development, but they cannot establish effectiveness in humans. The reported preclinical results also come from the treatment developer and must be interpreted in that context.

The clinical study, registered as NCT07748403, is a Phase 1/2 trial designed to investigate safety, tolerability, biological activity, and preliminary efficacy.

It is intended to include adults and adolescents with Wilson disease who carry at least one H1069Q allele. The initial participants are adults whose disease is clinically stable under standard treatment.

Researchers will evaluate increasing doses of PM577a and monitor both adverse events and changes in copper handling.

Possible measures include serum copper-related biomarkers, ceruloplasmin, urinary copper excretion, and PET imaging using radioactive copper-64.

The imaging approach is particularly relevant because it can help evaluate the movement and clearance of copper rather than relying entirely on indirect blood measurements.

Several questions will determine whether this strategy can become useful.

How many liver cells must be corrected to produce a meaningful improvement in copper metabolism?

How efficiently can the editing machinery reach hepatocytes after intravenous administration?

Will the treatment produce unintended genomic changes, immune reactions, or other adverse effects?

And will any improvement remain durable?

Because prime editing changes DNA, successful corrections could potentially persist for a long time. That prospect is central to its therapeutic appeal, but it also makes long-term safety monitoring particularly important.

Prime Medicine expects initial clinical data in 2027. As of October 2026, no patient-level results demonstrating successful editing or clinical efficacy with PM577a have been published.

Could one treatment replace lifelong disease management?

The broader significance of this trial lies in the prospect of correcting genetic disease directly within affected tissues.

Many inherited disorders arise from specific DNA changes. If precise genome editing can be delivered safely and effectively inside the body, it could expand the range of conditions amenable to genetic treatment.

That possibility remains dependent on the mutation, the affected tissue, and the available delivery technology.

PM577a, for example, is designed for H1069Q. It will not automatically correct every mutation that causes Wilson disease.

Prime Medicine is also developing a separate candidate targeting R778L, another important ATP7B mutation that is particularly prevalent in East Asian populations.

The immediate clinical question is narrower and more consequential than the broad promise of genome editing: can a single infusion restore functional ATP7B activity in enough liver cells to improve copper clearance?

For people with Wilson disease, current treatment largely means maintaining copper balance over a lifetime.

This trial is testing whether a molecular correction made once, inside the liver itself, could eventually change that equation.